Northern Trust Corp lifted its holdings in shares of Versartis, Inc. (NASDAQ:VSAR) by 15.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 420,553 shares of the biopharmaceutical company’s stock after acquiring an additional 56,761 shares during the quarter. Northern Trust Corp owned 1.19% of Versartis worth $7,339,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the stock. Artal Group S.A. increased its position in shares of Versartis by 16.7% during the second quarter. Artal Group S.A. now owns 350,000 shares of the biopharmaceutical company’s stock valued at $6,108,000 after acquiring an additional 50,000 shares during the last quarter. Emory University purchased a new stake in Versartis in the second quarter worth $1,709,000. Ameriprise Financial Inc. purchased a new stake in Versartis in the second quarter worth $1,530,000. TIAA CREF Investment Management LLC increased its position in Versartis by 63.1% in the second quarter. TIAA CREF Investment Management LLC now owns 288,960 shares of the biopharmaceutical company’s stock worth $5,042,000 after buying an additional 111,824 shares during the last quarter. Finally, Teachers Advisors LLC increased its position in Versartis by 29.1% in the second quarter. Teachers Advisors LLC now owns 71,317 shares of the biopharmaceutical company’s stock worth $1,244,000 after buying an additional 16,073 shares during the last quarter. 52.86% of the stock is owned by institutional investors.
In related news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of Versartis stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $3.29, for a total transaction of $7,007,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 2,132,769 shares of company stock valued at $7,014,761 in the last three months. 10.90% of the stock is owned by corporate insiders.
Versartis, Inc. (NASDAQ:VSAR) opened at $1.80 on Tuesday. Versartis, Inc. has a 52-week low of $1.60 and a 52-week high of $24.00. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.11.
Versartis (NASDAQ:VSAR) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.78). During the same quarter in the prior year, the company earned ($0.92) earnings per share. equities research analysts predict that Versartis, Inc. will post -4.14 EPS for the current fiscal year.
VSAR has been the subject of a number of recent research reports. Morgan Stanley reissued an “equal weight” rating and issued a $4.00 target price (up from $3.00) on shares of Versartis in a research report on Friday, September 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $14.00 target price (down from $34.00) on shares of Versartis in a research report on Friday, September 22nd. Piper Jaffray Companies reissued a “buy” rating and issued a $26.00 target price on shares of Versartis in a research report on Friday, September 8th. Zacks Investment Research downgraded Versartis from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Finally, Cowen and Company downgraded Versartis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $45.00 to $3.00 in a research report on Friday, September 22nd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.22.
TRADEMARK VIOLATION NOTICE: “Northern Trust Corp Has $7.34 Million Stake in Versartis, Inc. (VSAR)” was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.truebluetribune.com/2017/11/21/versartis-inc-vsar-stake-raised-by-northern-trust-corp-2.html.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.